The FDA recently announced its plans to investigate the type 2 diabetes drug Onglyza (saxagliptin) and its association with heart failure. The federal agency requested clinical trial data to analyze from the drug’s manufacturer, AstraZeneca. Our team of Onglyza lawyershopes that this investigation will lead to more restrictions on this dangerous drug. Onglyza is an oral …
Onglyza Study Finds No Cardiovascular Benefits
Defective drug lawyers at Pintas & Mullins Law Firm highlight a recent study examining AstraZeneca and Bristol-Myers Squibb’s cardiovascular drug Onglyza (the generic is saxagliptin), which found no cardiovascular benefits in patients when compared to a placebo. The trial, titled “SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza,” included 16,500 patients with type 2 diabetes and cardiovascular disease …